Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2017.01426
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

The Synergistic Antitumor Effect of Combined Anti-Human Epidermal Growth Factor Receptor 2 Antibody and Gamma Interferon Therapy on Antibody-Resistant Breast Cancer Cells

The Showa University Journal of Medical Sciences
2019English

Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2013English

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Frontiers in Immunology
AllergyImmunology
2018English

Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors

Clinical Cancer Research
Cancer ResearchOncology
2010English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Cancer
Cancer ResearchOncology
2019English

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2017English

Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells in Vitro

PLoS ONE
Multidisciplinary
2015English

Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2007English

Targeting the Human Epidermal Growth Factor Receptor 2 in Esophageal Cancer

Cancer Control
MedicineOncologyHematology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy